EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia

Sólja Remisdóttir Veyhe, Oriane Cédile iD, Sara Kamuk Dahlmann iD, Jakub Krejcik, Niels Abildgaard, Thor Høyer, Michael Boe Møller iD, Mads Thomassen, Karen Juul-Jensen, Henrik Frederiksen iD, Karen Dybkær iD, Marcus Høy Hansen iD und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252312569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sólja Remisdóttir Veyhe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense U…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Adenine, Piperidines, B-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Cancer Society, Helen Rudes Fund, OUH PhD Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells due to constitutive B-cell receptor (BCR) signaling, leading to apoptosis resistance and increased proliferation. This study evaluates the effects of the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib on the molecular composition, clonality, and kinetics of B cells during treatment in CLL patients. Employing a multi-omics approach of up to 3.2 years of follow-up, we analyzed data from 24 CLL patients, specifically focusing on nine patients treated with ibrutinib monotherapy. In this study, clonal stability was observed within the ibrutinib-treated group following an effective initial clinical response, where clonotype frequencies of residual CLL cells remained high and stable, ranging from 74.9% at 1.5 years to 87.7% at approximately 3 years. In contrast, patients treated with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax exhibited substantial reductions in clonal frequencies, approaching molecular eradication. Deep whole-exome sequencing revealed minimal genomic progression in the ibrutinib group, maintaining somatic drivers and variant allele frequencies (VAF) above 0.2 throughout treatment. At the single-cell level, the NF-κB pathway inhibition and apoptotic signals were detected or even augmented during treatment in ibrutinib-treated patients. These findings may corroborate the role of ibrutinib in stabilizing the genomic landscape of CLL cells, preventing significant genomic evolution despite maintaining a high clonal burden within the residual B-cell compartment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAdeninePiperidinesB-LymphocytesHumansAgedFemaleMaleMiddle AgedAgammaglobulinaemia Tyrosine KinasePyrimidinesPyrazolesProtein Kinase InhibitorsAged, 80 and overSulfonamidesBridged Bicyclo Compounds, HeterocyclicKineticsProto-Oncogene Proteins c-bcl-2Exome Sequencing

Stichwörter der Autor:innen

chronic lymphocytic leukemiaclonal stabilityibrutiniblymphocytosismolecular profilingtreatment efficacy

Substanzen

ibrutinibAdeninePiperidinesAgammaglobulinaemia Tyrosine KinasePyrimidinesPyrazolesProtein Kinase InhibitorsSulfonamidesvenetoclaxBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, 5000 Odense, Denmark.
  • Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark.
  • Department of Haematology, Odense University Hospital, 5000 Odense, Denmark.
  • Odense Patient Data Explorative Network (OPEN), Odense University Hospital, 5000 Odense, Denmark.
  • Department of Hematology, Aalborg University Hospital, 9000 Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University Hospital, 9000 Aalborg, Denmark.

ORCID-Profile: Oriane Cédile, Sara Kamuk Dahlmann, Michael Boe Møller, Henrik Frederiksen, Karen Dybkær, Marcus Høy Hansen, Charlotte Guldborg Nyvold

Förderung

  • Danish Cancer Society
  • Helen Rudes Fund
  • OUH PhD Fund
  • Dagmar Marshalls Fund
  • Agnes og Poul Friis Fund, Tornøe's og Høyrup's Fund
  • Marie og Børge Kroghs Fund
  • Torben og Alice Frimodts Fund
  • Danish Lymphoma Group Grant

Zitieren

APA

Veyhe, S. R., Cédile, O., Dahlmann, S. K., Krejcik, J., Abildgaard, N., Høyer, T., Møller, M. B., Thomassen, M., Juul-Jensen, K., Frederiksen, H., Dybkær, K., Hansen, M. H., & Nyvold, C. G. (2024). Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312569

Vancouver

Veyhe SR, Cédile O, Dahlmann SK, Krejcik J, Abildgaard N, Høyer T, et al. Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312569

BibTeX
@article{Veyhe2024,
  author = {Veyhe, Sólja Remisdóttir and Cédile, Oriane and Dahlmann, Sara Kamuk and Krejcik, Jakub and Abildgaard, Niels and Høyer, Thor and Møller, Michael Boe and Thomassen, Mads and Juul-Jensen, Karen and Frederiksen, Henrik and Dybkær, Karen and Hansen, Marcus Høy and Nyvold, Charlotte Guldborg},
  title = {Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252312569}
}
Kostenlos starten →